title: Orbital and ocular adnexal Mucosa-Associated Lymphoid Tissue (MALT) lymphomas: a single-center 10-year experience.
abstract: Orbital and ocular andexal Mucosa-Associated Lymphoid Tissue Lymphoma (MALT) or ocular adnexal MALT lymphoma (OAML) is the most common of all eye non-Hodgkin lymphomas. Autoimmune inflammatory disorders and chronic infections are important etiological factors and CD5 and CD43 (sialophorin) tumor markers are significant negative prognostic factors. Disease signs and symptoms can occur a long time before diagnosis. Varieties of treatment options are available. The aim of this retrospective analysis was to compare the efficiency of different treatment options and to investigate disease outcome. Twenty OAML patients, diagnosed in the Clinic of Hematology, Clinical Centre of Serbia, between 2003 and 2013, were enrolled. In most cases, OAML developed in the eighth decade with greater incidence in the male population. Median age was 67.5 years. The median period between the appearance of local signs and symptoms and diagnosis was 7 months. The dominant sign at presentation was swelling of involved tissue (40%). The most common was orbital involvement (55%). All patients had localized disease. Observed laboratory parameters on presentation showed low disease activity. Sialophorin prognostic significance was not registered. Our patients were initially treated differently but there was no significant difference in progression-free survival (PFS) due to initial treatment option (p = 0.2957). Median PFS was 22 months (3-89), and 5-year PFS was 60%. Median overall survival (OS) was 43 months (1-105) and 5-year OS 95%. Eight patients (40%) relapsed and one patient died due to non-hematological complications. In our experience, most modern induction treatment options appear to result in the same, favorable outcome.
authors.affiliation: Clinic of Hematology, Clinical Centre of Serbia, Belgrade, Serbia, mikesmiljanic79@gmail.com.
authors.forename: M
authors.initials: M
authors.lastname: Smiljanic
authors.forename: R
authors.initials: R
authors.lastname: Milosevic
authors.forename: D
authors.initials: D
authors.lastname: Antic
authors.forename: B
authors.initials: B
authors.lastname: Andjelic
authors.forename: V
authors.initials: V
authors.lastname: Djurasinovic
authors.forename: M
authors.initials: M
authors.lastname: Todorovic
authors.forename: J
authors.initials: J
authors.lastname: Bila
authors.forename: A
authors.initials: A
authors.lastname: Bogdanovic
authors.forename: B
authors.initials: B
authors.lastname: Mihaljevic
mesh_terms: D000328:Adult; D000368:Aged; D018450:Disease Progression; D018572:Disease-Free Survival; D005134:Eye Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome
references.citation: Ann Oncol. 2009 Apr;20(4):709-14
references.pmid: 19150940
references.citation: J Clin Oncol. 2012 Aug 20;30(24):2988-94
references.pmid: 22802315
references.citation: Ophthalmology. 2006 Jul;113(7):1209-13
references.pmid: 16647129
references.citation: Ann Oncol. 2006 Jan;17(1):135-40
references.pmid: 16236754
references.citation: Ophthalmology. 2007 Jan;114(1):182-6
references.pmid: 17198854
references.citation: Clin Exp Ophthalmol. 2001 Dec;29(6):387-93
references.pmid: 11778809
references.citation: Ann Oncol. 1998 Jul;9(7):779-81
references.pmid: 9739446
references.citation: Hum Pathol. 2007 Mar;38(3):435-42
references.pmid: 17217996
references.citation: Radiother Oncol. 2006 Jan;78(1):6-9
references.pmid: 16359744
references.citation: Br J Ophthalmol. 2008 Apr;92(4):534-6
references.pmid: 18369070
references.citation: N Engl J Med. 2000 Oct 26;343(17):1236-48
references.pmid: 11071676
references.citation: Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):657-63
references.pmid: 11849787
references.citation: Radiother Oncol. 2001 May;59(2):139-44
references.pmid: 11325441
references.citation: Mod Pathol. 2001 Jul;14(7):641-9
references.pmid: 11454995
references.citation: J Natl Cancer Inst. 2004 Apr 21;96(8):586-94
references.pmid: 15100336
references.citation: Crit Rev Oncog. 1998;9(3-4):269-73
references.pmid: 10201631
references.citation: Croat Med J. 2004 Jun;45(3):328-32
references.pmid: 15185428
references.citation: Ann Oncol. 2008 Feb;19(2):242-6
references.pmid: 17947227
references.citation: Eye (Lond). 2006 Jun;20(6):645-8
references.pmid: 16123786
references.citation: Blood. 2006 Jan 15;107(2):467-72
references.pmid: 16166588
references.citation: Cancer. 2003 Aug 15;98(4):865-71
references.pmid: 12910532
references.citation: J Natl Cancer Inst. 2006 Jul 5;98(13):936-9
references.pmid: 16818858
references.citation: J Pathol. 2006 Jul;209(3):344-51
references.pmid: 16583361
references.citation: Blood. 2006 Sep 1;108(5):1451-60
references.pmid: 16638927
references.citation: Ann Hematol. 2007 Aug;86(8):565-8
references.pmid: 17483948
references.citation: Ophthalmic Plast Reconstr Surg. 2004 Mar;20(2):103-6
references.pmid: 15083076
references.citation: Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1382-91
references.pmid: 14630277
references.citation: Int J Radiat Oncol Biol Phys. 1993 Apr 30;26(1):59-66
references.pmid: 8482631
references.citation: Br J Haematol. 2008 Jun;142(2):246-9
references.pmid: 18492114
references.citation: Blood. 2009 Jul 16;114(3):501-10
references.pmid: 19372259
references.citation: Ann Oncol. 2008 May;19(5):835-46
references.pmid: 17986622